Cupid Limited has initiated the Second 100-Day Campaign 'Saksham Niveshak' to facilitate dividend claims and KYC updates for shareholders, following directives from regulatory authorities. The company published regulatory intimation on April 17, 2026, to inform shareholders about this important initiative for unclaimed dividend recovery.

Campaign Overview and Objectives

The Investor Education and Protection Fund Authority (IEPFA) and Ministry of Corporate Affairs (MCA) requested companies through their circular dated March 27, 2026, to launch the Second 100-Day Campaign 'Saksham Niveshak'. The campaign specifically targets shareholders whose dividends remain unclaimed or unpaid, with emphasis on KYC updation and related compliance measures.

The objective of this initiative is to encourage shareholders to update their KYC details, bank mandates, and contact information to facilitate direct payment of unclaimed and unpaid dividends to rightful shareholders and prevent transfer to IEPF.

Documentation Requirements

The company has outlined specific forms and documents required for shareholders to claim their unpaid dividends:

Since dividend on shares is only payable in electronic mode, dividend will only be credited in shareholder's bank account after updating the required information and documents.

Process for Different Share Holdings

The company has outlined specific procedures for shareholders based on how they hold their shares:

Physical Share Holdings

Shareholders holding shares in physical form must submit applicable forms along with supporting documents to the company's Registrar and Share Transfer Agent.

Demat Share Holdings

For shares held in electronic form, shareholders need to update their KYC and other details with their respective Depository Participants (DP) to claim unclaimed dividends.

Documentation and Resources

The company has made required forms easily accessible to shareholders through their website at https://www.cupidlimited.com/kyc-forms-for-shareholders/ . Shareholders must fill in and deliver physical copies of these forms to the RTA at the specified address.

Regulatory Compliance

The intimation was issued under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Saurabh V. Karmase signed the regulatory intimation dated April 17, 2026, which was submitted to both BSE Limited and National Stock Exchange of India Ltd.

Call to Action

Cupid Limited encourages all shareholders to act promptly and submit their documents before July 9, 2026, to safeguard their entitlement and ensure compliance with statutory requirements. The initiative aims to prevent shareholders' dividends from being transferred to IEPF by ensuring proper documentation and contact information updates.

Alembic Pharmaceuticals has achieved a significant regulatory milestone with the receipt of final approval from the US Food and Drug Administration (FDA) for Methotrexate Injection USP. The company announced this development through a regulatory filing under Regulation 30, marking an important addition to its portfolio of injectable medications in the US market.

Product Specifications and Approval Details

The FDA approval encompasses comprehensive coverage for Methotrexate Injection USP with specific dosage formulations:

The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product of Hospira, Inc. This equivalence certification ensures that the generic version meets the same quality, safety, and efficacy standards as the original branded medication.

Therapeutic Applications and Indications

Methotrexate Injection serves as a folate analog metabolic inhibitor with extensive therapeutic applications across oncology and autoimmune conditions. The approved formulation is indicated for multiple neoplastic diseases including Acute Lymphoblastic Leukemia, Meningeal Leukemia (prophylaxis and treatment), Non-Hodgkin Lymphoma, Osteosarcoma, Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, and Gestational Trophoblastic Neoplasia. Additionally, the injection is indicated for treating rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and severe psoriasis.

Regulatory Portfolio Expansion

This latest approval brings Alembic Pharmaceuticals' cumulative total to 236 ANDA approvals from the USFDA, comprising 218 final approvals and 18 tentative approvals. The company's growing regulatory portfolio demonstrates its commitment to expanding access to essential medications in the US market while maintaining compliance with stringent FDA standards.

Market Significance

The final approval status indicates successful completion of all regulatory requirements and clinical evaluations necessary for commercial distribution in the United States. The dual-format approval for both multi-dose and single-dose vials positions Alembic Pharmaceuticals to serve diverse healthcare settings and patient needs, strengthening its presence in the competitive US injectable drugs market.